

Cipla launches Daptomycin for Injection

26 September 2019 | News

Daptomycin for Injection, 500mg/vial, single-dose vial for intravenous use only



Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), The pharmaceuticals and drug company, announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.

According to IQVIA (IMS Health), Cubicin® for Injection (daptomycin for injection) had U.S. sales of approximately \$606 Million for the 12-month period ending June 2019. The product is available for shipping immediately.